These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Dendritic cells and T cells in immunotherapy. O'Neill DW J Drugs Dermatol; 2010 Nov; 9(11):1383-92. PubMed ID: 21061761 [TBL] [Abstract][Full Text] [Related]
3. Cellular immunotherapy licensed for advanced prostate cancer. Traynor K Am J Health Syst Pharm; 2010 Jun; 67(11):862. PubMed ID: 20484204 [No Abstract] [Full Text] [Related]
4. Therapy: An immune one-two punch. Bourzac K Nature; 2015 Dec; 528(7582):S134-6. PubMed ID: 26672788 [No Abstract] [Full Text] [Related]
5. Immunotherapy for prostate cancer using antigen-loaded antigen-presenting cells: APC8015 (Provenge). Harzstark AL; Small EJ Expert Opin Biol Ther; 2007 Aug; 7(8):1275-80. PubMed ID: 17696825 [TBL] [Abstract][Full Text] [Related]
6. Landmark approval for Dendreon's cancer vaccine. DeFrancesco L Nat Biotechnol; 2010 Jun; 28(6):531-2. PubMed ID: 20531312 [No Abstract] [Full Text] [Related]
7. Biomarkers for the development of cancer vaccines: current status. Copier J; Whelan M; Dalgleish A Mol Diagn Ther; 2006; 10(6):337-43. PubMed ID: 17154650 [TBL] [Abstract][Full Text] [Related]
9. Sipuleucel-T: harbinger of a new age of therapeutics for prostate cancer. Madan RA; Gulley JL Expert Rev Vaccines; 2011 Feb; 10(2):141-50. PubMed ID: 21332262 [TBL] [Abstract][Full Text] [Related]
10. New treatments for metastic prostate cancer. Med Lett Drugs Ther; 2010 Sep; 52(1346):69-70. PubMed ID: 20814400 [TBL] [Abstract][Full Text] [Related]
11. Sipuleucel-T (Provenge): active cellular immunotherapy for advanced prostate cancer. McKarney I Issues Emerg Health Technol; 2007 Sep; (101):1-4. PubMed ID: 17763575 [TBL] [Abstract][Full Text] [Related]
12. Building on sipuleucel-T for immunologic treatment of castration-resistant prostate cancer. Shore ND; Mantz CA; Dosoretz DE; Fernandez E; Myslicki FA; McCoy C; Finkelstein SE; Fishman MN Cancer Control; 2013 Jan; 20(1):7-16. PubMed ID: 23302902 [TBL] [Abstract][Full Text] [Related]
13. Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy. Rini BI; Weinberg V; Fong L; Conry S; Hershberg RM; Small EJ Cancer; 2006 Jul; 107(1):67-74. PubMed ID: 16736512 [TBL] [Abstract][Full Text] [Related]
14. The delivery of effective therapeutic cancer vaccination. Hart D Asian J Androl; 2011 Mar; 13(2):183-4. PubMed ID: 21057515 [No Abstract] [Full Text] [Related]
15. Clinical development of immunotherapy for prostate cancer. Noguchi M; Koga N; Igawa T; Itoh K Int J Urol; 2017 Sep; 24(9):675-680. PubMed ID: 28636142 [TBL] [Abstract][Full Text] [Related]
16. Development of sipuleucel-T: autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer. Sims RB Vaccine; 2012 Jun; 30(29):4394-7. PubMed ID: 22122856 [TBL] [Abstract][Full Text] [Related]